Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $41.71, up 0.97% from its previous closing price of $41.31. In other words, the price has increased by $0.97 from its previous closing price. On the day, 1.69 million shares were traded. RNA stock price reached its highest trading level at $42.0 during the session, while it also had its lowest trading level at $41.09.
Ratios:
To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on August 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.Cantor Fitzgerald initiated its Overweight rating on March 14, 2024, with a $60 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 11 ’24 when Flanagan W. Michael sold 111,394 shares for $40.40 per share. The transaction valued at 4,500,244 led to the insider holds 60,871 shares of the business.
McCarthy Teresa sold 25,000 shares of RNA for $1,010,042 on Sep 11 ’24. The Chief Human Resources Officer now owns 57,171 shares after completing the transaction at $40.40 per share. On Sep 11 ’24, another insider, WILLIAM MICHAEL FLANAGAN, who serves as the Officer of the company, bought 111,394 shares for $40.79 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 4930914304 and an Enterprise Value of 3289152256. For the stock, the TTM Price-to-Sale (P/S) ratio is 460.86 while its Price-to-Book (P/B) ratio in mrq is 3.73. Its current Enterprise Value per Revenue stands at 310.327 whereas that against EBITDA is -11.636.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.80, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is -4.03%, while the 200-Day Moving Average is calculated to be 60.01%.
Shares Statistics:
It appears that RNA traded 1.50M shares on average per day over the past three months and 1006120 shares per day over the past ten days. A total of 117.12M shares are outstanding, with a floating share count of 108.77M. Insiders hold about 7.13% of the company’s shares, while institutions hold 93.20% stake in the company. Shares short for RNA as of 1724976000 were 10808414 with a Short Ratio of 7.19, compared to 1722384000 on 12952998. Therefore, it implies a Short% of Shares Outstanding of 10808414 and a Short% of Float of 11.3000005.
